Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation

April W Armstrong; Carly A Elston; Boni E Elewski; Laura K Ferris; Alice B Gottlieb; Mark G Lebwohl; Medical Board of the National Psoriasis Foundation

doi:10.1016/j.jaad.2023.09.080

Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation

J Am Acad Dermatol. 2024 Apr;90(4):727-730. doi: 10.1016/j.jaad.2023.09.080. Epub 2023 Oct 13.

Authors

April W Armstrong¹, Carly A Elston², Boni E Elewski², Laura K Ferris³, Alice B Gottlieb⁴, Mark G Lebwohl⁴; Medical Board of the National Psoriasis Foundation

Collaborators

Medical Board of the National Psoriasis Foundation:
Cassandra Calabrese, Seemal R Desai, Kristina C Duffin, Steven R Feldman, Dafna D Gladman, Brad P Glick, George Han, Jason Harris, Jason E Hawkes, Sylvia Hsu, Margaret Y Huang, Robert E Kalb, Leon H Kircik, John Koo, G Michael Lewitt, Wilson J Liao, Clive Liu, Joseph F Merola, Ronald B Prussick, Soumya M Reddy, Sergio Schwartzman, Jessica N Smith, Jennifer Soung, Abby S Van Voorhees, Elizabeth B Wallace, Jeffrey M Weinberg, Lara Wine Lee, Paul S Yamauchi

Affiliations

¹ Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California. Electronic address: armstrongpublication@gmail.com.
² Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama.
³ Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
⁴ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

PMID: 37838256
DOI: 10.1016/j.jaad.2023.09.080

No abstract available

Keywords: IL-36 inhibition; National Psoriasis Foundation; access; consensus statement; generalized pustular psoriasis; imsidolimab; psoriasis; spesolimab; therapy; treatment.

MeSH terms

Acute Disease
Chronic Disease
Consensus
Humans
Psoriasis* / diagnosis
Psoriasis* / drug therapy